By
Trending Posts
Can hellocare.ai and Epic’s Native Integration Redefine AI-Driven…
Key Takeaways Epic Integration Enhances Bedside Engagementhellocare.ai’s purpose-built virtual care device now supports Epic MyChart Bedside TV out…
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape…
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma…
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven…
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered…
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform…
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda…
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate…
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize…
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
Trending Posts
Latest Stories
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus Panel the Breakthrough for Fast, Decentralized Detection of Ebolavirus and Marburgvirus?
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million…
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI for 100 Million Patients?
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to…
Gallery
